11 results about "Purinergic receptor" patented technology

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

The invention discloses a multi-stimulation device for dysphagia rehabilitation training, and relates to the field of rehabilitation training instruments. According to the multi-stimulation device for dysphagia rehabilitation training, a user can load stimulation liquid with different cold and hot temperatures and various tastes in the liquid containing tank, the variety of the stimulation liquid connected into the guide pipe is changed by rotating the rotary drum, and therefore the stimulation liquid with different temperatures and the stimulation liquid with different tastes can be replaced; a heating wire and a semiconductor chilling plate are additionally arranged on the outer wall of the liquid containing tank, so that the liquid temperature is adjusted bidirectionally, and accurate cold and hot temperature control is achieved; a user can press the pumping assembly to pump the stimulation liquid into the bite pad through the guide pipe and the rotary drum, the stimulation liquid is sprayed out from the end of the massage block, a patient can bite the bite pad to receive alternate stimulation treatment of the stimulation liquid, the stimulation liquid with different tastes or different temperatures is rapidly alternated, a TRPV1 temperature-sensitive ion channel and a P2X3 purine receptor can be effectively activated, and the treatment effect is good. Signal transduction of a swallowing reflex arc is enhanced through double paths, and precise rehabilitation is achieved.

The present invention relates to a P2Y purinoceptor 2 (P2RY2) activity modulator for use in T cell immunotherapy. The present invention further relates to a polynucleotide encoding a P2RY2 activity modulator and to a host cell comprising the P2RY2 activity modulator for use in T cell immunotherapy. Furthermore, the present invention relates to a method of identifying 5 a subject amenable to T cell immunotherapy comprising (A) determining in a sample of said subject the activity of P2RY2; (B) comparing the activity determined in step (A) to a reference; and identifying a subject amenable to T cell immunotherapy based on the comparison of step (B), as well as to a method for identifying a P2RY2 activity modulator, said method comprising (I) contacting a host cell with a candidate compound suspected to be a P2RY2 activity 10 modulator; (II) determining B7-H3 activity in said host cell; (III) comparing the B7-H3 activity determined in step (II) to a control; and (IV) identifying a P2RY2 activity modulator based on the comparison in step (III).

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The present invention relates to compounds of Formula I (hereinafter referred to as P2X3 inhibitors) that inhibit P2X purinergic receptor 3; in particular, the present invention relates to compounds that are pyridopyrimidine derivatives, methods of making such compounds, pharmaceutical compositions containing them and therapeutic uses thereof. The compounds of the present invention are useful in the treatment of a number of disorders associated with P2X3 receptor mechanisms, such as respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

The present invention relates to adamantanyl-substituted benzamide compounds and their use as antagonists of the P2X7 purinoreceptor. The invention further relates to methods for the treatment of disease and conditions associated with the P2X7 purinoreceptor.

The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of diseases and conditions in which modulation of Ca2+-signaling plays a role, such as in some forms of spinocerebellar ataxia, and in diseases and conditions benefiting from mucosal hydration, as for example respiratory diseases and conditions, dry eye, xerostomia.

To provide an evaluation system capable of detecting an extracellular purinergic receptor ligand in a low invasive manner, over time and systemically.SOLUTION: There is provided a genetically modified non-human animal expressing a first fusion protein and a second fusion protein for detecting an extracellular purinergic receptor ligand, where the first fusion protein includes a membrane protein that binds to the purinergic receptor ligand and a first reporter protein, and the second fusion protein includes a protein that binds to the ligand-bound membrane protein and a second reporter protein, and there is also provided a cell thereof.SELECTED DRAWING: None

The purpose of the present invention is to provide an evaluation system capable of systematically detecting an extracellular purine receptor ligand over time with low invasiveness, and to provide a genetically modified non-human animal expressing a first fusion protein and a second fusion protein for detecting an extracellular purine receptor ligand, and a cell thereof. The first fusion protein contains a first reporter protein and a membrane protein that binds to a purine receptor ligand, and the second fusion protein contains a second reporter protein and a protein that binds to the membrane protein that binds to the ligand.